Data di Pubblicazione:
2023
Citazione:
Role of inhaled antibiotics in the era of highly effective CFTR modulators / J. Stuart Elborn, F.B.A. Blasi, P. Burgel, D. Peckham. - In: EUROPEAN RESPIRATORY REVIEW. - ISSN 1600-0617. - 32:167(2023), pp. 220154.1-220154.10. [10.1183/16000617.0154-2022]
Abstract:
Recurrent and chronic bacterial infections are common in people with cystic fibrosis (CF) and contribute to
lung function decline. Antibiotics are the mainstay in the treatment of exacerbations and chronic bacterial
infection in CF. Inhaled antibiotics are effective in treating chronic respiratory bacterial infections and
eradicating Pseudomonas aeruginosa from the respiratory tract, with limited systemic adverse effects. In
the past decade, highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators
have become a new therapy that partially corrects/opens chloride transport in patients with selected CFTR
mutations, restoring mucus hydration and improving mucociliary clearance. The recent triple CFTR
modulator combination is approved for ∼80–90% of the CF population and significantly reduces
pulmonary exacerbations and improves respiratory symptoms and lung function. CFTR modulators have
shifted the focus from symptomatic treatment to personalised/precision medicine by targeting genotype-
specific CFTR defects. While these are highly effective, they do not fully normalise lung physiology, stop
inflammation or resolve chronic lung damage, such as bronchiectasis. The impact of these new drugs on
lung health is likely to change the future management of chronic pulmonary infections in people with CF.
This article reviews the role of inhaled antibiotics in the era of CFTR modulators.
Tipologia IRIS:
01 - Articolo su periodico
Elenco autori:
J. Stuart Elborn, F.B.A. Blasi, P. Burgel, D. Peckham
Link alla scheda completa: